INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF Russian patent published in 2020 - IPC C07D403/12 C07D231/56 C07D401/12 C07D471/04 C07D487/04 C07D401/14 C07D498/04 A61K31/496 A61K31/416 A61K31/519 A61K31/4353 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: present invention relates to an indazole compound, specifically to a compound of formula I or its pharmaceutically acceptable salt I.

In formula I: L is selected from a group consisting of: H, tetrahydropyranyl (THP); each X is independently selected from a group consisting of: Cl, F and H; each of W and Z is independently selected from: N or CH; Y is CH; ring A is absent or is an unsubstituted or substituted 6 to 8-member arylene group, or an unsubstituted or substituted 5 to 8-member heteroarylene group, wherein said heteroarylene group contains at least one heteroatom, which is nitrogen; or , R is H or a substituted or unsubstituted group selected from a group consisting of:

,

where M is unsubstituted C1-C6-alkylene or M is absent. Term "substituted" in each case means that one or more hydrogen atoms in said group are substituted with a substitute selected from a group consisting of halogen, unsubstituted or halogenated C1-C6 alkyl, an unsubstituted or halogenated C1-C6 alkoxy group, an unsubstituted or halogenated C2-C6 alkoxyalkyl group, an unsubstituted or halogenated C3-C8 cycloalkyl group, unsubstituted or halogenated C2-C6-alkylcarbonyl group, unsubstituted or halogenated C1-C6-alkylene-hydroxy, unsubstituted or C1-C6-alkyl-substituted amino group. Also disclosed are a method of producing a compound of formula I, use thereof and pharmaceutical compositions.

EFFECT: compound according to the present invention has good FGFR kinase inhibitory activity, and can be used to produce a range of drugs for treating diseases associated with FGFR kinase activity.

13 cl, 2 tbl, 3 ex